HaemaLogiX Ltd has appointed Dr Chris Baldwin as chief executive officer and managing director, effective January 5, 2026, as the clinical-stage biotech progresses its novel immunotherapies for blood cancers and B-cell diseases.
Baldwin brings more than 20 years of experience across scientific research, operational leadership, capital markets and commercial strategy in Australia, Asia-Pacific, Europe and the United States.
He holds a PhD in chemical engineering from the University of Cambridge and was selected as a British Marshall Scholar. Baldwin began his career in academia as an associate professor of chemical engineering at Iowa State University before moving into industry with McKinsey & Company in New York.
His subsequent roles have included C-suite and founder positions across ASX-listed and international biotechnology and precision therapeutics companies, with experience spanning corporate and capital strategy, investor engagement, new market entry, partnership formation and product launches.
New CEO to help facilitate planned IPO
Further highlights include Baldwin’s Asia-Pacific portfolio management experience with medical device groups Terumo BCT and Haemonetics.
“On behalf of the Board, I am pleased to welcome Dr Chris Baldwin as CEO and Managing Director of HaemaLogiX. Chris brings a rare combination of deep scientific expertise and global commercial leadership, with a proven track record across global healthcare, biotechnology and technology-led organisations," executive chairman Dr John Cullity said.
"As we move into 2026, the Board is confident that Chris’ execution-focused leadership will strengthen the company’s foundations and position HaemaLogiX to deliver on our clinical, commercial and corporate objectives. Of course, key amongst these is our planned IPO.”
Baldwin said: “HaemaLogiX has built a compelling immunotherapy platform with the potential to address significant unmet needs for patients with blood cancers. I am excited to join the company at this important stage of growth and to work with the Board and team to advance our clinical programs, build strategic partnerships and create long-term value for patients and investors.”
HaemaLogiX was formed in 2014 and is a public unlisted biotech focused on antibody therapies for multiple myeloma, a blood cancer of plasma cells that is generally considered treatable but incurable.